Study S001213

An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT06289504
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 34
Start: 2024-02-27
Primary completion: 2024-10-16
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Atorvastatin; DRUG:Warfarin
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1295-4056

Registered primary outcomes

AUC0-72hours,atorv,SD: Area under the atorvastatin plasma concentration-time curve from time 0 to 72 hours after a single dose of atorvastatin without CagriSema exposure and at CagriSema steady state [Day 1 (pre-dose to 72 hours post-dose) and day 171 (pre-dose to 72 hours post-dose)]
AUC0-168hours,S-war,SD: Area under the S-warfarin plasma concentration-time curve from time 0 to 168 hours after a single dose of warfarin without CagriSema exposure and at CagriSema steady state [Day 8 (pre-dose to 168 hours post-dose) and day 178 (pre-dose to 168 hours post-dose)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.